Coronavirus / COVID

A brief overview of our recent coverage.

Opaganib is set to be evaluated against SARS-CoV-2 in a multi-center, randomized, parallel arm, double-blind, placebo-controlled study.

Researchers have found 6 inflammatory molecules in critically ill patients, which might be used as therapeutic targets in fighting COVID-19.

The status of emergency departments in the city during the pandemic's migration west.

Bradley Sherman, MD, shares insight as to what goes into a respiratory ventilator recovery unit.

Four human coronavirus infection rates were relatively consistent among all age groups older than 4 years, the study also found.

A brief summary of the latest news.

A look at how the state became a belated hotspot, and what may help reduce future infection growth.

A group of scientists hypothesize these shots could protect young children from the novel virus.

A European study shows a small amount of hospitalized children and adolescents with COVID-19 require intensive care and is rarely fatal.

A brief on today's top ID news.

The Hong Kong researchers used online searches to quantify public interest in mask usage.

The finger-prick test showed 98.8% specificity for novel coronavirus in assessments including 1500 patients.

Analysis suggests approach may be particularly useful when testing resources are limited.

Where did things go wrong for the Grand Canyon State?

A high proportion of N95 masks failed to fit properly with the extended use and reuse recommended by the CDC for conserving PPE during the shortage.

Video briefing on the day's top infectious disease news.

Given research into SARS-CoV-2 is taking place at unprecedented speed, the panel of IDSA experts had to decide on current best practices using science which is still in motion.

In a small randomized trial, Greek investigators found patients had improved time to clinical deterioration versus a control group.

Patrick Soon-Shiong, MD, Chairman and CEO of ImmunityBio, explains why the firm's COVID-19 research benefits from drawing on a background in cancer.

A recent review of electronic health data revealed a 42% drop in emergency department visits during 4 weeks of the pandemic.

An overview of today's top infectious disease stories.

Patrick Soon-Shiong, MD, CEO of ImmunityBio, discusses the pandemic as a unique moment in world & American history.

In order to expand the potential uses of the drug against SARS-CoV-2, Gilead Sciences has announced plans to explore administration of remdesivir in an inhaled form.

Thomas File, Jr. MD, MSc, FIDSA, president of the Infectious Diseases Society of America, weighs in on COVID vaccine development, fears of a second wave, and treatment candidates.